Recruiting patients to clinical trials: lessons from studies of growth hormone treatment in renal failure EDITOR,-We were interested in Professor Campbell's commentary on our recent paper.' Many of the important points he raises such as entry criteria, trial design, and patient selection were dealt with in the accompanying paper.2 It would have been helpful if we had made it clear that these two papers were companion papers by including more cross references. Neither report makes it clear that the studies had ethical committee approval and as Professor Campbell raises this point we can confirm that the protocols for both studies had been submitted separately to our local ethics committee and received its approval.
We disagree that 'some recruitment bias must have been introduced by the rather complex process of obtaining "staged" informed consent'. Our experience was the reverse. Inevitably it does take time to discuss such complicated issues adequately but the process does not need to be very complex: about 50% of our families required only a single interview. Thirty of 31 eligible patients took part in the psychological study and 28 of 31 eligible patients opted for treatment with growth hormone. Thus it was possible to involve families in the decision without biasing recruitment whilst protecting against families accepting uncritically prior decisions of the professionals. 
